Visgenx is developing therapeutics to protect against the loss of sight from retinal disorders. Our programs are based on increasing the expression of a gene which may prevent the loss of retinal cells critical for vision.
Age-related Macular Degeneration / Geographic Atrophy
Our fast-to-market approach is based on increasing gene expression using the de-methylating agent decitabine. Our longer term goal is gene therapy.